| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Q32 Bio Inc.
13D/A
QTTB · 746964105
|
3.6% |
5/28/2026
Event 5/26/2026
|
||||
| Atlas Venture Fund X, L.P. | 3.6% | |||||
| Atlas Venture Associates X, L.P. | 3.6% | |||||
| Atlas Venture Associates X, LLC | 3.6% | |||||
| Atlas Venture Opportunity Fund I, L.P. | 2.1% | |||||
| Atlas Venture Associates Opportunity I, L.P. | 2.1% | |||||
| Atlas Venture Associates Opportunity I, LLC | 2.1% | |||||
| Atlas Venture Opportunity Fund II, L.P. | 3.1% | |||||
| Atlas Venture Associates Opportunity II, L.P. | 3.1% | |||||
| Atlas Venture Associates Opportunity II, LLC | 3.1% | |||||
| Atlas Venture Opportunity Fund Ill, L.P. | 2.6% | |||||
| Atlas Venture Associates Opportunity III, L.P. | 2.6% | |||||
| Atlas Venture Associates Opportunity III, LLC | 2.6% | |||||
|
Disc Medicine, Inc.
13D/A
IRON · 254604101
|
2.2% |
12/17/2025
Event 12/12/2025
|
||||
| Atlas Venture Fund X, L.P. | 2.2% | |||||
| Atlas Venture Associates X, L.P. | 2.2% | |||||
| Atlas Venture Associates X, LLC | 2.2% | |||||
| Atlas Venture Fund XII, L.P. | 0% | |||||
| Atlas Venture Associates XII, L.P. | 0% | |||||
| Atlas Venture Associates XII, LLC | 0% | |||||
| Atlas Venture Opportunity Fund I, L.P. | 0.9% | |||||
| Atlas Venture Associates Opportunity I, L.P. | 0.9% | |||||
| Atlas Venture Associates Opportunity I, LLC | 0.9% | |||||
| Atlas Venture Opportunity Fund II, L.P. | 0.9% | |||||
| Atlas Venture Associates Opportunity II, LP | 0.9% | |||||
| Atlas Venture Associates Opportunity II, LLC | 0.9% | |||||
|
Imagenebio, Inc.
13D/A
IMA · 45175G207
|
2.1% |
7/29/2025
Event 7/25/2025
|
||||
| Atlas Venture Fund X, L.P. | 2.1% | |||||
| Atlas Venture Associates X, L.P. | 2.1% | |||||
| Atlas Venture Associates X, LLC | 2.1% | |||||
| Atlas Venture Fund XI, L.P. | 0.9% | |||||
| Atlas Venture Associates XI, L.P. | 0.9% | |||||
| Atlas Venture Associates XI, LLC | 0.9% | |||||
| Atlas Venture Opportunity Fund I, L.P. | 0.6% | |||||
| Atlas Venture Associates Opportunity I, L.P. | 0.6% | |||||
| Atlas Venture Associates Opportunity I, LLC | 0.6% | |||||
| Schedule 13G · 3 securities · passive | ||||||
|
Kymera Therapeutics, Inc.
13G/A
KYMR · 501575104
|
2.9% |
8/13/2026
Event 6/30/2026
|
||||
| Atlas Venture Fund X, L.P. | 2.9% | |||||
| Atlas Venture Associates X, L.P. | 2.9% | |||||
| Atlas Venture Associates X, LLC | 2.9% | |||||
| Atlas Venture Opportunity Fund I, L.P. | 0.6% | |||||
| Atlas Venture Associates Opportunity I, L.P. | 0.6% | |||||
| Atlas Venture Associates Opportunity I, LLC | 0.6% | |||||
|
Obsidian Therapeutics, Inc.
13G
OBX · 67448A106
|
4.3% |
8/10/2026
Event 8/3/2026
|
||||
| Atlas Venture Fund X, L.P. | 4.3% | |||||
| Atlas Venture Associates X, L.P. | 4.3% | |||||
| Atlas Venture Associates X, LLC | 4.3% | |||||
| Atlas Venture Opportunity Fund I, L.P. | 1.7% | |||||
| Atlas Venture Associates Opportunity I, L.P. | 1.7% | |||||
| Atlas Venture Associates Opportunity I, LLC | 1.7% | |||||
| Atlas Venture Opportunity Fund II, L.P. | 0.9% | |||||
| Atlas Venture Associates Opportunity II, L.P. | 0.9% | |||||
| Atlas Venture Associates Opportunity II, LLC | 0.9% | |||||
| Atlas Venture Opportunity Fund III, L.P. | 0.3% | |||||
| Atlas Venture Associates Opportunity III, L.P. | 0.3% | |||||
| Atlas Venture Associates Opportunity III, LLC | 0.3% | |||||
|
Generation Bio Co.
13G/A
GBIO · 37148K100
|
0% |
5/14/2026
Event 3/31/2026
|
||||
| Atlas Venture Fund X, L.P. | 0% | |||||
| Atlas Venture Associates X, L.P. | 0% | |||||
| Atlas Venture Associates X, LLC | 0% | |||||
| Atlas Venture Opportunity Fund I, L.P. | 0% | |||||
| Atlas Venture Associates Opportunity I, L.P. | 0% | |||||
| Atlas Venture Associates Opportunity I, LLC | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.